{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:09:27Z","timestamp":1782364167174,"version":"3.54.5"},"reference-count":45,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,8,23]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ORAL Strategy (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02187055\">NCT02187055<\/jats:ext-link>), a phase IIIB\/IV, head-to-head, randomised controlled trial, assessed non-inferiority between tofacitinib 5 mg two times per day monotherapy, tofacitinib 5 mg two times per day+MTX and ADA 40 mg every other week+MTX. PROs assessed included the following: Patient Global Assessment of disease activity (PtGA), Pain, Health Assessment Questionnaire-Disability Index, Functional Assessment of Chronic Illness Therapy-Fatigue and 36-Item Short-Form Health Survey (SF-36) summary and domain scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Substantial improvements from baseline were reported across all PROs in all treatment arms, which, in the majority, met or exceeded minimum clinically important differences. Compared with tofacitinib monotherapy, tofacitinib+MTX combination treatment conferred significantly greater improvements in PtGA, Pain and SF-36 physical component summary scores at month 6. Statistically or numerically greater improvements were often, but not uniformly, reported for combination treatments compared with tofacitinib monotherapy at other time points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with tofacitinib+MTX, ADA+MTX and tofacitinib monotherapy resulted in clinically meaningful improvements in PROs in MTX-IR patients with RA. These were comparatively greater with combination treatments versus tofacitinib monotherapy, although differences between treatment arms were small, limiting our ability to confer clinical meaning.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02187055\">NCT02187055<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001040","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T23:26:45Z","timestamp":1569972405000},"page":"e001040","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vibeke","family":"Strand","sequence":"first","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Reumat\u00f3logo en Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-6211","authenticated-orcid":false,"given":"Robert J","family":"Moots","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene V","family":"Wallenstein","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DeMasi","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshika","family":"Soma","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iikuni","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2025090312415148000_5.2.e001040.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204627"},{"key":"2025090312415148000_5.2.e001040.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312415148000_5.2.e001040.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090312415148000_5.2.e001040.4","doi-asserted-by":"crossref","first-page":"8417249","DOI":"10.1155\/2017\/8417249","article-title":"Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis","volume":"2017","author":"Bergrath","year":"2017","journal-title":"Int J Rheumatol"},{"key":"2025090312415148000_5.2.e001040.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2025090312415148000_5.2.e001040.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"2025090312415148000_5.2.e001040.7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled optima trial","volume":"383","author":"Smolen","year":"2014","journal-title":"The Lancet"},{"key":"2025090312415148000_5.2.e001040.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"2025090312415148000_5.2.e001040.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"2025090312415148000_5.2.e001040.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101161"},{"key":"2025090312415148000_5.2.e001040.11","first-page":"2343","article-title":"Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis","volume":"34","author":"Mittendorf","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312415148000_5.2.e001040.12","first-page":"2317","article-title":"Longterm treatment benefits are best reflected by patient reported outcomes","volume":"34","author":"Strand","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312415148000_5.2.e001040.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209322"},{"key":"2025090312415148000_5.2.e001040.14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"The Lancet"},{"key":"2025090312415148000_5.2.e001040.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312415148000_5.2.e001040.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312415148000_5.2.e001040.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312415148000_5.2.e001040.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312415148000_5.2.e001040.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312415148000_5.2.e001040.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0825-9","article-title":"Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312415148000_5.2.e001040.21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22453"},{"key":"2025090312415148000_5.2.e001040.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev442"},{"key":"2025090312415148000_5.2.e001040.23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000308","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial","volume":"2","author":"Strand","year":"2016","journal-title":"RMD Open"},{"key":"2025090312415148000_5.2.e001040.24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23004","article-title":"Tofacitinib in combination with conventional disease\u2010modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient\u2010reported outcomes from a phase III randomized controlled trial","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312415148000_5.2.e001040.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2025090312415148000_5.2.e001040.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312415148000_5.2.e001040.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312415148000_5.2.e001040.28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"The Lancet"},{"key":"2025090312415148000_5.2.e001040.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090312415148000_5.2.e001040.30","first-page":"590","article-title":"Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis","volume":"32","author":"Strand","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090312415148000_5.2.e001040.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069690"},{"key":"2025090312415148000_5.2.e001040.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.20048"},{"key":"2025090312415148000_5.2.e001040.33","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312415148000_5.2.e001040.34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"key":"2025090312415148000_5.2.e001040.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120964"},{"key":"2025090312415148000_5.2.e001040.36","unstructured":"Maruish ME . User's Manual for the SF-36v2\u00ae Health Survey. In: QualityMetric Incorporated: Lincoln, RI, 3rd Ed, 2011."},{"key":"2025090312415148000_5.2.e001040.37","unstructured":"Ware JE , Kosinski M , Dewey JE . How to score version two of the SF-36 health survey. In: QualityMetric Incorporated: Lincoln, RI, 2000."},{"key":"2025090312415148000_5.2.e001040.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.107805"},{"key":"2025090312415148000_5.2.e001040.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141440"},{"key":"2025090312415148000_5.2.e001040.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2025090312415148000_5.2.e001040.41","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090312415148000_5.2.e001040.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140976"},{"key":"2025090312415148000_5.2.e001040.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1004-3","article-title":"Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity","volume":"18","author":"Smolen","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312415148000_5.2.e001040.44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000551","article-title":"Discordant patient\u2013physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis","volume":"3","author":"Karpouzas","year":"2017","journal-title":"RMD Open"},{"key":"2025090312415148000_5.2.e001040.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211259"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:42:00Z","timestamp":1756928520000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/rmdopen-2019-001040"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001040","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}